KR910004185A - 세포독소 약제에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그 사용 - Google Patents
세포독소 약제에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그 사용 Download PDFInfo
- Publication number
- KR910004185A KR910004185A KR1019900012981A KR900012981A KR910004185A KR 910004185 A KR910004185 A KR 910004185A KR 1019900012981 A KR1019900012981 A KR 1019900012981A KR 900012981 A KR900012981 A KR 900012981A KR 910004185 A KR910004185 A KR 910004185A
- Authority
- KR
- South Korea
- Prior art keywords
- cytotoxin
- compound
- toremifene
- compounds
- cancer cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 24시간 노출후 CHO-k1() 및 CHO-Adr() 세포계 내에서 토레미펜의 농도 증가의 효과를 나타낸 그래프이다. (닫힌 기호는 AAG(2㎎/㎖)의 부재를 나타내고, 열린 기호는 AAG의 존재를 나타낸다.)
Claims (11)
- 적어도 하나의 세포독소 화합물을 사용한 암치료에 있어서, 상기 세포독소 화합물에 대한 암세포의 다약제 내성의 역전을 위한 토레미펜, N-데메틸토레미펜, 4-히드록시 토레미펜 또는 이들의 제약학적으로 허용가능한 비-독성 염의 사용.
- 제1항에 있어서, 토레미펜의 사용.
- 제1항 또는 제2항에 있어서, 세포독소 화합물이 알킬화제, 항핵분열제, 항대사물, 플라티늄 화합물 또는 항생제인 사용.
- 제3항에 있어서, 항생제가 안트라시클린 항생물질인 사용.
- 제4항에 있어서, 안트라시클린항생물질이 독소루비신인 사용.
- (a) 토레미펜. N-데메틸-토레미펜, 4-히드록시토레미펜 또는 이들의 제약학적으로 허용가능한 비-독성염. (b) (a) 이외의 세포독소 화합물 및, (c) 제약학적으로 허용가능한 담체 또는 희석제로 구성된 제약학적 상승 조성물.
- 제6항에 있어서, (b)가 제3항 또는 제4항에서 정의된 바와같은 세포독소화합물인 조성물.
- 제6항에 있어서, (b)가 독소루비신인 화합물.
- 암치료에 있어서 동시적, 별도의 또는 연속적 사용을 위해 조합된 제제로서, (a)토레미펜, N-데메틸토레미펜 또는 4-히드록시 토레미펜 또는 이들의 제약학적으로 허용가능한 비-독성 염, 및 (b) (a) 이외의 세포독소 화합물을 함유한 생성물.
- 제9항에 있어서, (b)가 제3항 또는 제4항에서 정의된 바와 같은 세포독소화합물인 생성물.
- 제10항에 있어서, (b)가 독소루비신인 생성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US397551 | 1989-08-23 | ||
US07/397,551 US4990538A (en) | 1989-08-23 | 1989-08-23 | Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
KR910004185A true KR910004185A (ko) | 1991-03-28 |
KR0171893B1 KR0171893B1 (ko) | 1999-02-01 |
Family
ID=23571649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900012981A KR0171893B1 (ko) | 1989-08-23 | 1990-08-22 | 세포장해성 약물에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그를 포함하는 제약학적 조성물 |
Country Status (11)
Country | Link |
---|---|
US (1) | US4990538A (ko) |
EP (1) | EP0415623A3 (ko) |
JP (1) | JP3186759B2 (ko) |
KR (1) | KR0171893B1 (ko) |
AU (1) | AU633954B2 (ko) |
CA (1) | CA2023630C (ko) |
HU (1) | HU215913B (ko) |
IE (1) | IE67639B1 (ko) |
NZ (1) | NZ234999A (ko) |
PH (1) | PH27064A (ko) |
ZA (1) | ZA906670B (ko) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5491173A (en) * | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
US5114951A (en) * | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
US5162581A (en) * | 1989-05-29 | 1992-11-10 | Takaru Shuzo Co., Ltd. | Crystalline deoxyspergualin, process for its preparation and suppository containing the same |
GB8914062D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
GB8914060D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
GB8914061D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
GB8914040D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
US5114919A (en) * | 1990-02-26 | 1992-05-19 | Merck & Co., Inc. | Adjuncts in cancer chemotherapy |
ITRM910192A1 (it) * | 1990-04-03 | 1991-10-04 | American Cyanamid Co | Metodo per invertire la resistenza a bisantrene mediata da p-glicoproteine. |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) * | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
CA2129143C (en) * | 1992-02-06 | 1997-05-06 | Sai Prasad Sunkara | Reversal of multi-drug resistance by tetraarylethylenes |
GB9207437D0 (en) * | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
US5770609A (en) * | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6395494B1 (en) * | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
US5840319A (en) * | 1992-10-08 | 1998-11-24 | Alakhov; Valery Yu | Biological agent compositions |
AU5286693A (en) * | 1992-10-27 | 1994-05-24 | Nippon Kayaku Kabushiki Kaisha | Use of non steroidal anti estrogens for autoimmune diseases |
US5886049A (en) * | 1992-10-27 | 1999-03-23 | Nippon Kayaku Kabushiki Kaisha | Remedy for autoimmune diseases |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
JPH08510451A (ja) * | 1993-05-13 | 1996-11-05 | ネオルックス コーポレイション | 異常増殖性平滑筋細胞に関連した病因の予防及び治療 |
US6197789B1 (en) | 1995-06-07 | 2001-03-06 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
US5436243A (en) * | 1993-11-17 | 1995-07-25 | Research Triangle Institute Duke University | Aminoanthraquinone derivatives to combat multidrug resistance |
US5432168A (en) * | 1993-12-27 | 1995-07-11 | University Of Manitoba | Method of treatment of hormone-unresponsive metastatic prostate cancer |
US5650425A (en) * | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
US5571687A (en) * | 1994-06-07 | 1996-11-05 | Duke University | Modulators of multidrug resistance transporters |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5767113A (en) * | 1995-05-10 | 1998-06-16 | The Salk Institute For Biological Studies | Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance |
WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US6632447B1 (en) | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
US20040176470A1 (en) * | 1998-05-07 | 2004-09-09 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20030130316A1 (en) * | 2000-03-20 | 2003-07-10 | Steiner Mitchell S. | Method for chemoprevention of prostate cancer |
WO1999056739A1 (en) * | 1998-05-07 | 1999-11-11 | The University Of Tennessee Research Corporation | A method for chemoprevention of prostate cancer |
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US6413534B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
WO2000030684A1 (fr) * | 1998-11-26 | 2000-06-02 | Teikoku Hormone Mfg. Co., Ltd. | Compositions medicamenteuses a administration periodique |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
EP3779446A1 (en) * | 2013-12-11 | 2021-02-17 | University of Massachusetts | Compositions and methods for treating disease using salmonella t3ss effector protein (sipa) |
CA2971216A1 (en) | 2014-12-23 | 2016-06-30 | The Regents Of The University Of California | Methods for immunomodulation of cancer and infectious disease therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0680016B2 (ja) * | 1984-08-02 | 1994-10-12 | ラブリ−,フエルナンド | ホルモン依存性がんの併用治療のための医薬組成物 |
-
1989
- 1989-08-23 US US07/397,551 patent/US4990538A/en not_active Expired - Lifetime
-
1990
- 1990-08-20 AU AU61133/90A patent/AU633954B2/en not_active Ceased
- 1990-08-20 CA CA002023630A patent/CA2023630C/en not_active Expired - Lifetime
- 1990-08-21 JP JP22092690A patent/JP3186759B2/ja not_active Expired - Fee Related
- 1990-08-21 EP EP19900309119 patent/EP0415623A3/en not_active Withdrawn
- 1990-08-21 NZ NZ234999A patent/NZ234999A/en unknown
- 1990-08-22 ZA ZA906670A patent/ZA906670B/xx unknown
- 1990-08-22 HU HU905276A patent/HU215913B/hu not_active IP Right Cessation
- 1990-08-22 KR KR1019900012981A patent/KR0171893B1/ko not_active IP Right Cessation
- 1990-08-22 IE IE304490A patent/IE67639B1/en not_active IP Right Cessation
- 1990-08-23 PH PH41068A patent/PH27064A/en unknown
Also Published As
Publication number | Publication date |
---|---|
HU905276D0 (en) | 1991-02-28 |
EP0415623A2 (en) | 1991-03-06 |
ZA906670B (en) | 1991-06-26 |
AU633954B2 (en) | 1993-02-11 |
JP3186759B2 (ja) | 2001-07-11 |
HUT58511A (en) | 1992-03-30 |
IE67639B1 (en) | 1996-04-17 |
CA2023630A1 (en) | 1991-02-24 |
US4990538A (en) | 1991-02-05 |
KR0171893B1 (ko) | 1999-02-01 |
HU215913B (hu) | 1999-03-29 |
EP0415623A3 (en) | 1991-04-03 |
AU6113390A (en) | 1991-02-28 |
IE903044A1 (en) | 1991-02-27 |
NZ234999A (en) | 1997-06-24 |
CA2023630C (en) | 2002-02-19 |
PH27064A (en) | 1993-02-01 |
JPH03163015A (ja) | 1991-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR910004185A (ko) | 세포독소 약제에 대항하는 암세포의 다약제 내성의 역전을 위한 화합물 및 그 사용 | |
CA1075157A (en) | Veterinary composition containing mono-saccharide | |
ES2602956T3 (es) | Composiciones de antibiótico para tratamiento de conjuntivitis | |
IL80149A (en) | Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases | |
KR920002144A (ko) | 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제 | |
Bryan et al. | Gentamicin accumulation by sensitive strains of Escherichia coli and Pseudomonas aeruginosa | |
KR920702216A (ko) | 아세틸 d-카르니틴의 녹내장 치료에의 용도 | |
KR920007629A (ko) | SALMe염, 5-MTHF 및 5-FTHF 중에서 선택된 화합물 적어도 1개를 유효성분으로서 함유하여 AIDS환자의 신경학적 질환치료시 활성을 나타내는 약제학적 조성물 | |
HU9400430D0 (en) | New pyrazine derivatives, their preparation and pharmaceutical compositions containing them | |
BR9811137A (pt) | Processo para redução de hiperglicemia e processo para redução de hiperglicemia e estabilização do nìvel de glicose sérica, composição farmacêutica, e, uso de tripicolinato crÈmico sintético | |
Garin et al. | Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy | |
IL42313A (en) | Pharmaceutical composition containing glycyrrhetinic acid for the treatment of oesophagitis | |
ES2142430T3 (es) | Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral. | |
Palmer et al. | Partial prevention by cyanide of selenium poisoning in rats | |
KR890008136A (ko) | 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체 | |
DE3777365D1 (de) | Einspritzbare fertig brauchbare loesungen, die ein antracyclineglykosid als mittel gegen krebs enthalten. | |
US3577537A (en) | Topical administration of vitamin b-12 | |
IE43125L (en) | Aminoglycoside derivative | |
Raghuram et al. | Effect of vitamin C on paracetamol hepatotoxicity | |
IE800344L (en) | Anti-perspirant compositions | |
Zundel et al. | Derivatives and analogues of benzaldehyde selectively cytotoxic to SV-40 transformed cells | |
RU94036762A (ru) | Гетероарилпиперидины, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция | |
Broun et al. | Transmission of St. Louis Encephalitis to the hamster | |
Angel | Short-course chemotherapy in pulmonary tuberculosis | |
FR2391208A1 (fr) | Thiophenes substitues et compositions pharmaceutiques en contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080922 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |